Edge Capital Group LLC Has $2.57 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Edge Capital Group LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 622.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,096 shares of the medical research company’s stock after acquiring an additional 11,284 shares during the quarter. Edge Capital Group LLC’s holdings in IQVIA were worth $2,573,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. South Dakota Investment Council bought a new position in IQVIA during the fourth quarter worth about $2,462,000. Howard Capital Management Inc. grew its holdings in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the period. Abound Financial LLC bought a new position in IQVIA during the fourth quarter worth about $512,000. Invera Wealth Advisors LLC grew its holdings in IQVIA by 0.7% during the fourth quarter. Invera Wealth Advisors LLC now owns 14,098 shares of the medical research company’s stock worth $2,904,000 after purchasing an additional 102 shares during the period. Finally, Cumberland Partners Ltd grew its holdings in IQVIA by 6.0% during the fourth quarter. Cumberland Partners Ltd now owns 1,759 shares of the medical research company’s stock worth $346,000 after purchasing an additional 99 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IQV. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Price Performance

IQV stock opened at $190.94 on Monday. The stock has a market capitalization of $33.62 billion, a PE ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company’s 50-day moving average is $199.57 and its 200-day moving average is $216.25. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.